Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23+ lymphoma cell lines No significant financial relationships to disclose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results